Inactive Instrument

All News OXIS International, Inc. Other OTC

Equities

US6918294025

End-of-day quote Other OTC Other stock markets
- ^USD	-

26/03	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01/02	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	16/05	AQ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	27/03	AQ
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	01/02	MT
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	01/02	AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	07/12	AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	06/12	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12	CI
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	07/11	AQ
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	06/11	AQ
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	06/11	CI
GT Biopharma Reports Third Quarter 2023 Financial Results	01/11	AQ
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	23/23/23	PU
GT Biopharma Reports Second Quarter 2023 Financial Results	07/23/07	AQ
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023	03/23/03	AQ
GT Biopharma : Submission of Matters to a Vote of Security Holders - Form 8-K	05/23/05	PU
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index	23/23/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News OXIS International, Inc. Other OTC

Equities

US6918294025

All News

Filters